Insights into Hepatocellular Carcinoma (HCC) 2020 (Midwest)

Current treatment practice attitudes toward therapy of unresectable advanced hepatocellular carcinoma (HCC), recently introduced and upcoming agents

Midwest – November 4, 2020

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Scottsdale, Az

Example Report

Start discovering the insights

View Report


  • A roundtable discussion moderated by an Axess Oncology Network physician focusing on treatment of HCC was held on November 4, 2020, in a virtual setting
  • Disease state and data presentations were developed in conjunction with Tanios Bekaii-Saab, MD, a medical expert from the Mayo Clinic in Phoenix, Arizona
  • The group of advisors comprised 12 community oncologists from the midwest United States
  • Insights on the following therapies were obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab


  • Data collection was accomplished through use of audience response system (ARS) questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from Illinois, Michigan, Ohio, and Indiana

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.